PT2018874E - Composições farmacêuticas para a prevenção e tratamento de distúrbios no sistema nervoso central que compreendem um agonista nicotínico e um inibidor de acetilcolinesterase - Google Patents

Composições farmacêuticas para a prevenção e tratamento de distúrbios no sistema nervoso central que compreendem um agonista nicotínico e um inibidor de acetilcolinesterase Download PDF

Info

Publication number
PT2018874E
PT2018874E PT80199144T PT08019914T PT2018874E PT 2018874 E PT2018874 E PT 2018874E PT 80199144 T PT80199144 T PT 80199144T PT 08019914 T PT08019914 T PT 08019914T PT 2018874 E PT2018874 E PT 2018874E
Authority
PT
Portugal
Prior art keywords
acetylcholinesterase inhibitor
prevention
treatment
pharmaceutical compositions
nervous system
Prior art date
Application number
PT80199144T
Other languages
English (en)
Inventor
Marouane Bencherif
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of PT2018874E publication Critical patent/PT2018874E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PT80199144T 1998-08-07 1999-06-02 Composições farmacêuticas para a prevenção e tratamento de distúrbios no sistema nervoso central que compreendem um agonista nicotínico e um inibidor de acetilcolinesterase PT2018874E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/130,498 US6218383B1 (en) 1998-08-07 1998-08-07 Pharmaceutical compositions for the prevention and treatment of central nervous system disorders

Publications (1)

Publication Number Publication Date
PT2018874E true PT2018874E (pt) 2014-10-16

Family

ID=22444976

Family Applications (2)

Application Number Title Priority Date Filing Date
PT80199144T PT2018874E (pt) 1998-08-07 1999-06-02 Composições farmacêuticas para a prevenção e tratamento de distúrbios no sistema nervoso central que compreendem um agonista nicotínico e um inibidor de acetilcolinesterase
PT99965348T PT1102588E (pt) 1998-08-07 1999-06-02 Composições farmacêuticas para a prevenção e tratamento de distúrbios no sistema nervoso central que compreendem um análogo de nicotina e um inibidor de acetilcolinesterase

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT99965348T PT1102588E (pt) 1998-08-07 1999-06-02 Composições farmacêuticas para a prevenção e tratamento de distúrbios no sistema nervoso central que compreendem um análogo de nicotina e um inibidor de acetilcolinesterase

Country Status (15)

Country Link
US (1) US6218383B1 (pt)
EP (2) EP1102588B1 (pt)
JP (2) JP4750945B2 (pt)
KR (1) KR100705434B1 (pt)
AT (1) ATE418986T1 (pt)
AU (1) AU761087B2 (pt)
BR (1) BR9912805A (pt)
CA (1) CA2335012C (pt)
CY (2) CY1110309T1 (pt)
DE (1) DE69940199D1 (pt)
DK (2) DK1102588T3 (pt)
ES (2) ES2515120T3 (pt)
MX (1) MXPA01001435A (pt)
PT (2) PT2018874E (pt)
WO (1) WO2000007600A1 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979695B2 (en) * 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
US20020052497A1 (en) * 2000-03-09 2002-05-02 Targacept, Inc. Compounds capable of activating cholinergic receptors
US7790757B2 (en) * 1998-06-16 2010-09-07 Targacept, Inc. Compounds capable of activating cholinergic receptors
US6232316B1 (en) 1998-06-16 2001-05-15 Targacept, Inc. Methods for treatment of CNS disorders
US20050131034A1 (en) * 1998-06-16 2005-06-16 Caldwell William S. Compounds capable of activating cholinergic receptors
US20010031771A1 (en) 1999-05-24 2001-10-18 Gary Maurice Dull Pharmaceutical compositions and methods for use
JP2003501416A (ja) * 1999-06-07 2003-01-14 ターガセプト，インコーポレイテッド 医薬組成物およびその使用法
US20010036949A1 (en) * 2000-05-09 2001-11-01 Coe Jotham Wadsworth Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
EP1463481A4 (en) * 2001-12-14 2008-06-25 Targacept Inc METHOD AND COMPOSITIONS FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM
US7091357B2 (en) 2001-12-26 2006-08-15 University Of Kentucky Research Foundation Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
US6852741B2 (en) * 2001-12-31 2005-02-08 University Of Florida Compositions and methods for treatment of neurological disorders
US20030162770A1 (en) 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
DE10212564B4 (de) * 2002-03-12 2007-04-19 Neurobiotec Gmbh 1-Allyl-ergotalkaloid-Derivate und ihre Verwendung zur Prophylaxe und Therapie von Migräne
US20030186860A1 (en) * 2002-03-29 2003-10-02 Welsh Michael J. Novel compositions and methods for modulating the acid-sensing ion channel (ASIC)
US20070197583A1 (en) * 2002-03-29 2007-08-23 Welsh Michael J Novel compositions and methods for modulation of the acid-sensing ion channel (ASIC) for the treatment of anxiety and drug addiction
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
CN1960684B (zh) * 2004-04-02 2013-11-06 动脉再塑技术公司 基于聚合物的支架装置
UA88792C2 (ru) 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
TWI389889B (zh) 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
US8017785B2 (en) 2006-05-09 2011-09-13 Astrazeneca Ab Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
US20080167286A1 (en) * 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
WO2008091592A1 (en) * 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
JP4110198B2 (ja) * 2007-07-27 2008-07-02 株式会社東芝 半導体発光装置
WO2009017455A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor
JP5701607B2 (ja) 2007-12-07 2015-04-15 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー アミドメチル置換オキシインドール誘導体およびバソプレッシン依存性疾患の治療へのこれらの使用
EP2231644B1 (de) 2007-12-07 2014-01-15 AbbVie Deutschland GmbH & Co KG 5,6-Disubstitutierte Oxindol-Derivate und ihre Verwendung zur Herstellung eines Medikaments zur Behandlung von Vasopressin-abhängigen Erkrankungen
KR20100097195A (ko) 2007-12-07 2010-09-02 애보트 게엠베하 운트 콤파니 카게 ５－할로겐－치환된 옥스인돌 유도체 및 바소프레신－의존성 질병을 치료하기 위한 이의 용도
WO2010009775A1 (de) 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
US20090291150A1 (en) * 2008-05-21 2009-11-26 University Of Iowa Research Foundation Method and compositions for treating and preventing seizures by modulating acid-sensing ion channel activity
US9801865B2 (en) 2008-09-24 2017-10-31 The United States Of America As Represented By The Department Of Veteran Affairs Materials and methods for diagnosis, prevention and/or treatment of stress disorders and conditions associated with abeta peptide aggregation
EP2435080A2 (en) 2009-05-29 2012-04-04 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
EA202092673A3 (ru) 2010-02-09 2021-05-31 Дзе Джонс Хопкинс Юниверсити Способы и композиции для улучшения когнитивной функции
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
US8703802B2 (en) 2010-05-20 2014-04-22 Targacept, Inc. Process for the preparation of aryl substituted olefinic amines
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
US11260050B2 (en) 2017-02-16 2022-03-01 United States Government As Represented By The Department Of Veterans Affairs Combination of cotinine plus antioxidant for treatment-resistant depression and correction of astrocytes functional deficit induced by depression and other neuropathological
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US560423A (en) 1896-05-19 peirce
US4965074A (en) * 1985-03-05 1990-10-23 Ciba-Geigy Corporation Method of treating memory impairment
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DK569087A (da) 1986-10-31 1988-05-01 Sumitomo Pharma Quinolin-derivater, deres fremstilling og anvendelse
EP0363415B1 (en) 1987-05-04 2008-10-15 Davis, Bonnie Compounds for the treatment of alzheimer's disease
HU201906B (en) 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
PH25124A (en) 1987-03-17 1991-02-19 Hoechst Roussel Pharma Substituted 9-amino-tetrahydro acridines and related compounds
IT1225462B (it) 1987-04-03 1990-11-14 Mediolanum Farmaceutici Srl Sali organici di derivati della fisostigmina
US5002955A (en) 1987-04-23 1991-03-26 Hoechst-Roussel Pharmaceuticals Inc. Fused heteroalkylene quinolinamines and use as cholinergic agents
US5187165A (en) 1987-05-15 1993-02-16 Hoechst-Roussel Pharmaceuticals Inc. Memory enhancing and analgesic 1,2,3a,8,8a-hexahydro-3a,8(and 1,3a,8)-di(and tri)methylpyrrolo[2,3-b]indoles
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
EP0403713A1 (en) 1989-06-22 1990-12-27 Merrell Dow Pharmaceuticals Inc. Novel acetylcholinesterase inhibitors
US5693668A (en) 1989-06-22 1997-12-02 Merrell Pharmaceuticals Inc. Acetylcholinesterase inhibitors
US4999430A (en) 1989-07-31 1991-03-12 Warner-Lambert Company Derivatives of 1,2,3,4-tetrahydro-9-acrisinamine
DE3927049A1 (de) 1989-08-16 1991-02-21 Sandoz Ag Halogenalkyl-phenyl-ketone und deren hydrate, ihre herstellung und verwendung
US4914102A (en) 1989-09-28 1990-04-03 Hoechst Roussel Pharmaceuticals, Inc. N-aminocarbamates related to physostigmine, pharmacentical compositions and use
NZ237241A (en) 1990-03-02 1993-11-25 Pharmetrix Corp Method for increasing the storage stability of physostigmine
US5102891A (en) 1990-07-23 1992-04-07 Hoechst-Roussel Pharmaceuticals Inc. 1-(substituted pyridinylamino)-1H-indol-5-yl substituted carbamates
US5264442A (en) 1990-08-13 1993-11-23 Hoechst-Roussel Pharmaceuticals Incorporated Carbamoyl-1-(pyridinylalkyl)-1H-indoles, indolines and related analogs
TW200462B (pt) 1990-09-27 1993-02-21 Hoechst Roussel Pharma
US5190951A (en) 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
JP2657583B2 (ja) 1991-03-01 1997-09-24 ユニバーシテイ オブ フロリダ リサーチ ファンデーション インコーポレイテッド 神経系変性疾患の治療に対するニコチン類似体の利用
FR2677019B1 (fr) 1991-05-27 1994-11-25 Pf Medicament Nouvelles piperidines disubstituees-1,4, leur preparation et leur application en therapeutique.
ES2153360T3 (es) 1991-05-29 2001-03-01 Abbott Lab Compuestos de isoxazol e de isotiazol que mejoran las funciones de razonamiento.
FR2679555B1 (fr) 1991-07-25 1993-11-19 Fabre Medicament Pierre Nouveaux derives de l'uree, leur preparation et leur application en therapeutique.
US5246947A (en) 1991-09-23 1993-09-21 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino-1,2-benzisothiazoles and their use for treating depression
US5231093A (en) 1991-10-01 1993-07-27 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
TW263504B (pt) 1991-10-03 1995-11-21 Pfizer
US5413098A (en) 1991-12-24 1995-05-09 Sextant Medical Corporation Path constrained spectrophotometer and method for determination of spatial distribution of light or other radiation scattering and absorbing substances in a radiation scattering medium
ES2042384B1 (es) 1991-12-26 1994-06-01 Boehringer Ingelheim Espana Procedimiento para obtener derivados bis-piridinicos.
EP0619814A1 (en) 1991-12-31 1994-10-19 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
CA2129732A1 (en) 1992-02-25 1993-09-02 Alain Martin Cytoprotective compositions containing pyruvate and antioxidants
US5212188A (en) 1992-03-02 1993-05-18 R. J. Reynolds Tabacco Company Method for treatment of neurodegenerative diseases
US5242935A (en) 1992-03-06 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5276043A (en) 1992-04-10 1994-01-04 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5227391A (en) 1992-04-10 1993-07-13 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
IT1254996B (it) 1992-06-25 1995-10-11 Mediolanum Farmaceutici Srl Esteri amminoalchilcarbammici dell'eserolina atti all'impiego come anticolinesterasici e relativo procedimento di preparazione
US5242916A (en) * 1992-07-07 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5466696A (en) 1992-09-10 1995-11-14 Warner Lambert Company Tacrine and cytochrome P450 oxidase inhibitors and methods of use
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
DE4301782C1 (de) * 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
IT1264765B1 (it) * 1993-03-10 1996-10-04 Rotta Research Lab Derivati dell'acido glutammico ed acido aspartico, procedimento per la loro preparazione e loro uso come farmaci potenzianti la
EP0627400A1 (en) 1993-06-04 1994-12-07 Merrell Dow Pharmaceuticals Inc. Aromatic acetylcholinesterase inhibitors
SE9302080D0 (sv) 1993-06-16 1993-06-16 Ab Astra New compounds
EP0711166A1 (en) * 1993-07-22 1996-05-15 Warner-Lambert Company Controlled release tacrine drug delivery systems and methods for preparing same
US5434170A (en) 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
US5744476A (en) 1994-06-27 1998-04-28 Interneuron Pharmaceuticals, Inc. Dopamine D1 agonists for the treatment of dementia
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5616707A (en) 1995-01-06 1997-04-01 Crooks; Peter A. Compounds which are useful for prevention and treatment of central nervous system disorders
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
WO1996030372A1 (en) 1995-03-24 1996-10-03 Japan Tobacco Inc. Diazabicyclo[3.3.1]nonane derivatives and intermediates thereof, medicinal use of the same, and processes for producing the same
JP2668670B2 (ja) * 1995-03-24 1997-10-27 日本たばこ産業株式会社 ジアザビシクロ［３．３．１］ノナン誘導体、その中間体及びその医薬用途
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
WO1997019059A1 (en) 1995-11-17 1997-05-29 Sibia Neurosciences, Inc. Novel substituted aryl compounds useful as modulators of acetylcholine receptors
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
CA2252039C (en) 1996-04-12 2002-12-24 Hoechst Marion Roussel, Inc. Isatin derivatives as acetylcholinesterase inhibitors and analgesics
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
CA2180703A1 (en) 1996-07-08 1998-01-09 Paul Marie Victor Gilis Fast-dissolving galanthamine hydrobromide tablet
CA2289574C (en) * 1997-05-30 2007-04-24 Neurosearch A/S 8-azabicyclo(3,2,1)oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ach receptors
US7727473B2 (en) 2005-10-19 2010-06-01 Progentech Limited Cassette for sample preparation
JP5597919B2 (ja) * 2008-11-05 2014-10-01 株式会社三洋物産 制御基板の収納構造

Also Published As

Publication number Publication date
EP1102588B1 (en) 2008-12-31
HK1127290A1 (en) 2009-09-25
DK1102588T3 (da) 2009-04-14
ATE418986T1 (de) 2009-01-15
WO2000007600A1 (en) 2000-02-17
EP2018874B1 (en) 2014-08-13
KR20010072631A (ko) 2001-07-31
AU4328599A (en) 2000-02-28
JP2002522390A (ja) 2002-07-23
PT1102588E (pt) 2009-02-26
CA2335012C (en) 2009-08-11
EP2018874A3 (en) 2012-11-21
JP4750945B2 (ja) 2011-08-17
EP1102588A1 (en) 2001-05-30
AU761087B2 (en) 2003-05-29
JP2011137027A (ja) 2011-07-14
US6218383B1 (en) 2001-04-17
DK2018874T3 (da) 2014-10-13
DE69940199D1 (de) 2009-02-12
CY1110309T1 (el) 2015-01-14
BR9912805A (pt) 2001-05-02
EP2018874A2 (en) 2009-01-28
CY1115589T1 (el) 2017-01-04
CA2335012A1 (en) 2000-02-17
ES2322725T3 (es) 2009-06-25
KR100705434B1 (ko) 2007-04-09
ES2515120T3 (es) 2014-10-29
MXPA01001435A (es) 2003-09-10

Similar Documents

Publication Publication Date Title
PT2018874E (pt) Composições farmacêuticas para a prevenção e tratamento de distúrbios no sistema nervoso central que compreendem um agonista nicotínico e um inibidor de acetilcolinesterase
NZ332780A (en) Substituted amines for the treatment of neurological and neuropsychiatric disorders
WO1997004780A3 (en) Pain-alleviating drug composition and method for alleviating pain
IL125735A0 (en) Pharmaceutical compositions for the treatment of glaucoma
AU4645596A (en) Pharmaceutical compositions for prevention and treatment of central nervous system disorders
HUP0103856A3 (en) Pharmaceutical composition for the treatment of acute disorders
HU9803018D0 (en) Methods and compositions for the treatment and prevention of tumors, tumor-veloted disorders and cachexia
AU3495397A (en) Muscarinic antagonists
EP0807633A3 (en) Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones
GB2311940B (en) Pharmaceutical compositions for the treatment of rhinitis
UA66872C2 (uk) Сполука, яка є памоатом оланзапіну або його сольватом, та спосіб лікування психотичних розладів
EP1032556A4 (en) PHARMACEUTICALLY EFFECTIVE COMPOUNDS AND METHODS OF THEIR APPLICATION
AU5383196A (en) Pharmaceutical compositions for prevention and treatment of central nervous system disorders
BG103687A (en) Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative processes and conditions related to the central nervous system
WO2001092274A3 (en) Naaladase inhibitors for treating retinal disorders and glaucoma
BG105962A (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
BG106548A (en) Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog
MX9708394A (es) Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion.
IL142803A0 (en) Pharmaceutical compositions containing r-tofisopam
IL116828A (en) Use of 3, 4-diphenyl chromans for the preparation of pharmaceutical compositions for the treatment or prophylaxis of cerebral degenerative disorders
EE200000290A (et) Toimeainete, nimelt tetrahüdropüridiinide ja atsetüülkoliinesteraasi inhibiitorite, kombinatsioon Alzheimeri tõve tüüpi seniildementsuse raviks
AU2961199A (en) Hiv cofactor inhibitors and medicinal compositions for preventing or treating hiv-infection
MY130725A (en) Composition and method for treating allergic diseases
HUP0101748A3 (en) Use of reboxetine for producing pharmaceutical compositions suitable for treating nervous disorders
ZA98682B (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting one or more psychiatric disorders